Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions
MDGL Stock Forecast
Madrigal Pharmaceuticals stock forecast is as follows: an average price target of $315.75 (represents a 29.46% upside from MDGL’s last price of $243.89) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
MDGL Price Target
The average price target for Madrigal Pharmaceuticals (MDGL) is $315.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $410.00 to $111.00. This represents a potential 29.46% upside from MDGL's last price of $243.89.
MDGL Analyst Ratings
According to 12 Wall Street analysts, Madrigal Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MDGL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (75.00%), 3 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Madrigal Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 29, 2024 | Yasmeen Rahimi | Piper Sandler | $336.00 | $221.75 | 51.52% | 37.77% |
| May 09, 2024 | Ed Acre | H.C. Wainwright | $390.00 | $208.04 | 87.46% | 59.91% |
| Mar 19, 2024 | Liisa Bayko | Evercore ISI | $405.00 | $265.68 | 52.44% | 66.06% |
| Mar 15, 2024 | Eliana Merle | UBS | $410.00 | $270.37 | 51.64% | 68.11% |
| Mar 15, 2024 | Akash Tewari | Jefferies | $400.00 | $270.37 | 47.95% | 64.01% |
| Mar 15, 2024 | Ed Acre | H.C. Wainwright | $425.00 | $270.37 | 57.19% | 74.26% |
| Mar 15, 2024 | Jonathan Wolleben | JMP Securities | $397.00 | $270.37 | 46.84% | 62.78% |
| Mar 15, 2024 | Mayank Mamtani | B.Riley Financial | $270.00 | $270.37 | -0.14% | 10.71% |
| Jan 05, 2023 | - | JMP Securities | $390.00 | $274.48 | 42.09% | 59.91% |
| Dec 21, 2022 | - | UBS | $337.00 | $257.12 | 31.07% | 38.18% |
The latest Madrigal Pharmaceuticals stock forecast, released on May 29, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $336.00, which represents a 51.52% increase from the stock price at the time of the forecast ($221.75), and a 37.77% increase from MDGL last price ($243.89).
Madrigal Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 8 |
| Avg Price Target | - | - | $379.13 |
| Last Closing Price | $243.89 | $243.89 | $243.89 |
| Upside/Downside | -100.00% | -100.00% | 55.45% |
In the current month, the average price target of Madrigal Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Madrigal Pharmaceuticals's last price of $243.89. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 16, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 28, 2024 | Cantor Fitzgerald | - | Neutral | Initialise |
| Jun 10, 2024 | Wolfe Research | - | Outperform | Initialise |
| Jun 06, 2024 | Citigroup | Buy | Buy | Hold |
| May 29, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 10, 2024 | B. Riley | Neutral | Neutral | Hold |
| May 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 22, 2024 | Bank of America Securities | - | Underperform | Initialise |
| Dec 21, 2022 | UBS | Buy | Buy | Hold |
| Dec 20, 2022 | Oppenheimer | Buy | Buy | Hold |
Madrigal Pharmaceuticals's last stock rating was published by JMP Securities on Jul 16, 2024. The company gave MDGL a "Outperform" rating, the same as its previous rate.
Madrigal Pharmaceuticals Financial Forecast
Madrigal Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 17 | Mar 17 | Mar 16 | Jun 14 | Mar 14 | Sep 13 | Jun 13 | Mar 13 | Sep 12 | Jun 12 | Mar 12 | Dec 11 | Sep 11 | Jun 11 | Mar 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $147.00K | $3.42M | $1.66M | $1.35M | $1.14M |
| Avg Forecast | $128.76M | $108.53M | $90.10M | $69.55M | $54.91M | $31.29M | $4.25M | $114.77K | - | $4.83M | $4.34M | $4.62M | $5.19M | $6.67M | $5.69M | $1.41M | $2.95M | $1.82M | $3.27M | $5.45M | $3.87M | $3.74M | $3.46M | $139.10K | $156.24K | $91.32K | $4.13M | $1.61M | $905.33K | $1.13M |
| High Forecast | $212.96M | $179.50M | $149.02M | $115.04M | $90.82M | $51.90M | $7.04M | $189.82K | - | $5.80M | $5.21M | $5.55M | $6.23M | $8.00M | $6.82M | $1.69M | $3.54M | $2.19M | $3.92M | $6.54M | $4.65M | $4.49M | $4.15M | $166.92K | $187.49K | $109.59K | $4.95M | $1.94M | $1.09M | $1.36M |
| Low Forecast | $92.39M | $77.87M | $64.65M | $49.91M | $39.40M | $23.63M | $3.05M | $82.35K | - | $3.87M | $3.48M | $3.70M | $4.15M | $5.33M | $4.55M | $1.13M | $2.36M | $1.46M | $2.61M | $4.36M | $3.10M | $2.99M | $2.77M | $111.28K | $124.99K | $73.06K | $3.30M | $1.29M | $724.26K | $907.00K |
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 15 | 16 | 14 | 13 | 11 | 12 | 15 | 8 | 10 | 11 | 17 | 15 | 9 | 12 | 15 | 18 | 20 | 20 | 9 | 12 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.61% | 0.83% | 1.03% | 1.50% | 1.01% |
Madrigal Pharmaceuticals's average Quarter revenue forecast for Jun 12 based on 18 analysts is $156.24K, with a low forecast of $124.99K, and a high forecast of $187.49K. MDGL's average Quarter revenue forecast represents a 6.29% increase compared to the company's last Quarter revenue of $147.00K (Mar 12).
Madrigal Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 17 | Mar 17 | Mar 16 | Jun 14 | Mar 14 | Sep 13 | Jun 13 | Mar 13 | Sep 12 | Jun 12 | Mar 12 | Dec 11 | Sep 11 | Jun 11 | Mar 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 15 | 16 | 14 | 13 | 11 | 12 | 15 | 8 | 10 | 11 | 17 | 15 | 9 | 12 | 15 | 18 | 20 | 20 | 9 | 12 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-57.85M | $-48.91M | $-25.50M | $-21.40M | $-19.67M | $-15.05M | $-8.35M | $-6.00M | $-6.40M | $-21.53M | $-22.74M | $-21.65M | $-21.94M | $-20.16M | $-14.37M | $-14.40M | $-14.82M | $-9.95M | $-11.87M | $-11.63M | $-10.53M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $-50.67M | $-35.25M | $-27.21M | $-26.23M | $-21.16M | $-17.90M | $-7.09M | $-7.70M | $-12.80M | $-23.68M | $-23.26M | $-19.97M | $-19.32M | $-17.70M | $-13.55M | $-14.73M | $-13.41M | $-11.70M | $-11.24M | $-5.80M | $-10.84M |
| High Forecast | - | - | - | - | - | - | - | - | - | $-40.54M | $-28.20M | $-21.76M | $-20.99M | $-16.93M | $-14.32M | $-5.68M | $-6.16M | $-10.24M | $-18.94M | $-18.61M | $-15.98M | $-15.46M | $-14.16M | $-10.84M | $-11.79M | $-10.73M | $-9.36M | $-8.99M | $-4.64M | $-8.67M |
| Low Forecast | - | - | - | - | - | - | - | - | - | $-60.80M | $-42.30M | $-32.65M | $-31.48M | $-25.40M | $-21.49M | $-8.51M | $-9.23M | $-15.36M | $-28.41M | $-27.91M | $-23.96M | $-23.19M | $-21.24M | $-16.26M | $-17.68M | $-16.10M | $-14.04M | $-13.48M | $-6.96M | $-13.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 1.39% | 0.94% | 0.82% | 0.93% | 0.84% | 1.18% | 0.78% | 0.50% | 0.91% | 0.98% | 1.08% | 1.14% | 1.14% | 1.06% | 0.98% | 1.10% | 0.85% | 1.06% | 2.00% | 0.97% |
undefined analysts predict MDGL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Madrigal Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Madrigal Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 17 | Mar 17 | Mar 16 | Jun 14 | Mar 14 | Sep 13 | Jun 13 | Mar 13 | Sep 12 | Jun 12 | Mar 12 | Dec 11 | Sep 11 | Jun 11 | Mar 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 15 | 16 | 14 | 13 | 11 | 12 | 15 | 8 | 10 | 11 | 17 | 15 | 9 | 12 | 15 | 18 | 20 | 20 | 9 | 12 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | $-57.96M | $-49.02M | $-27.74M | $-21.43M | $-19.70M | $-15.08M | $-8.35M | $-6.00M | $-6.52M | $-22.29M | $-23.56M | $-22.52M | $-22.79M | $-20.73M | $-15.00M | $-14.62M | $-15.05M | $-10.74M | $-12.73M | $-12.50M | $-11.40M |
| Avg Forecast | $-81.10M | $-94.80M | $-106.53M | $-125.68M | $-129.84M | $-150.85M | $-161.30M | $-134.52M | $-103.52M | $-50.06M | $-34.42M | $-25.22M | $-23.26M | $-18.39M | $-14.92M | $-7.09M | $-7.70M | $-13.05M | $-24.51M | $-24.10M | $-20.77M | $-20.07M | $-18.20M | $-14.14M | $-15.48M | $-13.62M | $-12.64M | $-12.06M | $-6.24M | $-11.74M |
| High Forecast | $-51.32M | $-59.99M | $-67.41M | $-79.53M | $-82.17M | $-132.35M | $-102.07M | $-85.12M | $-97.30M | $-40.05M | $-27.53M | $-20.17M | $-18.61M | $-14.71M | $-11.94M | $-5.68M | $-6.16M | $-10.44M | $-19.61M | $-19.28M | $-16.62M | $-16.06M | $-14.56M | $-11.32M | $-12.39M | $-10.90M | $-10.11M | $-9.65M | $-4.99M | $-9.39M |
| Low Forecast | $-150.04M | $-175.40M | $-197.09M | $-232.52M | $-240.23M | $-225.29M | $-298.43M | $-248.87M | $-113.64M | $-60.07M | $-41.30M | $-30.26M | $-27.91M | $-22.06M | $-17.91M | $-8.51M | $-9.23M | $-15.66M | $-29.41M | $-28.92M | $-24.93M | $-24.09M | $-21.84M | $-16.97M | $-18.58M | $-16.35M | $-15.17M | $-14.47M | $-7.49M | $-14.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 1.42% | 1.10% | 0.92% | 1.07% | 1.01% | 1.18% | 0.78% | 0.50% | 0.91% | 0.98% | 1.08% | 1.14% | 1.14% | 1.06% | 0.94% | 1.10% | 0.85% | 1.06% | 2.00% | 0.97% |
Madrigal Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDGL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Madrigal Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 17 | Mar 17 | Mar 16 | Jun 14 | Mar 14 | Sep 13 | Jun 13 | Mar 13 | Sep 12 | Jun 12 | Mar 12 | Dec 11 | Sep 11 | Jun 11 | Mar 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 15 | 16 | 14 | 13 | 11 | 12 | 15 | 8 | 10 | 11 | 17 | 15 | 9 | 12 | 15 | 18 | 20 | 20 | 9 | 12 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | $5.49M | $5.64M | $5.04M | $4.75M | $7.11M | $5.75M | $1.62M | $1.70M | $3.04M | $2.94M | $5.32M | $4.17M | $4.19M | $3.88M | $2.80M | $2.88M | $2.65M | $2.80M | $3.13M | $2.95M | $2.67M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $4.74M | $3.96M | $4.59M | $5.15M | $6.64M | $5.69M | $1.38M | $2.17M | - | $3.23M | $5.45M | $3.85M | $3.69M | $3.41M | - | - | - | $3.30M | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | $5.69M | $4.75M | $5.50M | $6.18M | $7.96M | $6.82M | $1.66M | $2.61M | - | $3.88M | $6.54M | $4.62M | $4.43M | $4.09M | - | - | - | $3.96M | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | $3.80M | $3.17M | $3.67M | $4.12M | $5.31M | $4.55M | $1.10M | $1.74M | - | $2.59M | $4.36M | $3.08M | $2.95M | $2.72M | - | - | - | $2.64M | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 1.42% | 1.10% | 0.92% | 1.07% | 1.01% | 1.18% | 0.78% | - | 0.91% | 0.98% | 1.08% | 1.14% | 1.14% | - | - | - | 0.85% | - | - | - |
Madrigal Pharmaceuticals's average Quarter SG&A projection for Dec 23 is -, based on 11 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to MDGL last annual SG&A of $5.49M (Sep 20).
Madrigal Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 17 | Mar 17 | Mar 16 | Jun 14 | Mar 14 | Sep 13 | Jun 13 | Mar 13 | Sep 12 | Jun 12 | Mar 12 | Dec 11 | Sep 11 | Jun 11 | Mar 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 15 | 16 | 14 | 13 | 11 | 12 | 15 | 8 | 10 | 11 | 17 | 15 | 9 | 12 | 15 | 18 | 20 | 20 | 9 | 12 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | $-3.75 | $-3.18 | $-1.80 | $-1.39 | $-1.28 | $-0.98 | $-0.69 | $-0.50 | $-1.75 | $-8.40 | $-9.80 | $-11.55 | $-11.55 | $-10.50 | $-8.75 | $-8.75 | $-9.45 | $-6.67 | $-10.50 | $-10.50 | $-9.45 |
| Avg Forecast | $-3.79 | $-4.43 | $-4.98 | $-5.87 | $-6.07 | $-7.05 | $-7.54 | $-6.29 | $-5.24 | $-3.39 | $-2.45 | $-1.67 | $-1.42 | $-1.30 | $-1.00 | $-0.51 | $-1.12 | $-2.10 | $-10.26 | $-10.26 | $-9.89 | $-9.09 | $-8.22 | $-7.81 | $-9.85 | $-7.81 | $-11.00 | $-9.44 | $-3.39 | $-10.03 |
| High Forecast | $-2.40 | $-2.80 | $-3.15 | $-3.72 | $-3.84 | $-6.18 | $-4.77 | $-3.98 | $-4.92 | $-0.06 | $-0.05 | $-0.03 | $-0.03 | $-0.02 | $-0.02 | $-0.41 | $-0.89 | $-1.68 | $-8.21 | $-8.21 | $-7.91 | $-7.27 | $-6.58 | $-6.25 | $-7.88 | $-6.25 | $-8.80 | $-7.55 | $-2.71 | $-8.02 |
| Low Forecast | $-7.01 | $-8.20 | $-9.21 | $-10.86 | $-11.22 | $-10.53 | $-13.94 | $-11.63 | $-5.75 | $-5.30 | $-3.83 | $-2.61 | $-2.23 | $-2.04 | $-1.56 | $-0.61 | $-1.34 | $-2.52 | $-12.31 | $-12.31 | $-11.87 | $-10.91 | $-9.86 | $-9.37 | $-11.82 | $-9.37 | $-13.20 | $-11.33 | $-4.07 | $-12.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.11% | 1.30% | 1.08% | 0.98% | 0.98% | 0.98% | 1.35% | 0.45% | 0.83% | 0.82% | 0.96% | 1.17% | 1.27% | 1.28% | 1.12% | 0.89% | 1.21% | 0.61% | 1.11% | 3.10% | 0.94% |
According to undefined Wall Street analysts, Madrigal Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDGL previous annual EPS of $NaN (undefined).
Madrigal Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.72 | $70.00 | 9622.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| PLRX | Pliant Therapeutics | $12.87 | $40.50 | 214.69% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| ETNB | 89bio | $8.47 | $22.00 | 159.74% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| IOVA | Iovance Biotherapeutics | $10.01 | $21.57 | 115.48% | Buy |
| VKTX | Viking Therapeutics | $54.13 | $100.50 | 85.66% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| PTCT | PTC Therapeutics | $31.54 | $44.33 | 40.55% | Hold |
| SRPT | Sarepta Therapeutics | $128.92 | $169.93 | 31.81% | Buy |
| MDGL | Madrigal Pharmaceuticals | $243.89 | $315.75 | 29.46% | Buy |
| TGTX | TG Therapeutics | $22.03 | $26.40 | 19.84% | Buy |
| KRYS | Krystal Biotech | $184.19 | $187.00 | 1.53% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
MDGL Forecast FAQ
Is Madrigal Pharmaceuticals a good buy?
Yes, according to 12 Wall Street analysts, Madrigal Pharmaceuticals (MDGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 75.00% of MDGL's total ratings.
What is MDGL's price target?
Madrigal Pharmaceuticals (MDGL) average price target is $315.75 with a range of $111 to $410, implying a 29.46% from its last price of $243.89. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Madrigal Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for MDGL stock, the company can go up by 29.46% (from the last price of $243.89 to the average price target of $315.75), up by 68.11% based on the highest stock price target, and down by -54.49% based on the lowest stock price target.
Can Madrigal Pharmaceuticals stock reach $400?
MDGL's highest twelve months analyst stock price target of $410 supports the claim that Madrigal Pharmaceuticals can reach $400 in the near future.
What are Madrigal Pharmaceuticals's analysts' financial forecasts?
Madrigal Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $90.57M (high $149.95M, low $66.17M), average EBITDA is $0 (high $0, low $0), average net income is $-577M (high $-402M, low $-1.013B), average SG&A $0 (high $0, low $0), and average EPS is $-26.937 (high $-18.769, low $-47.322). MDGL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $396.94M (high $656.52M, low $284.82M), average EBITDA is $0 (high $0, low $0), average net income is $-408M (high $-258M, low $-755M), average SG&A $0 (high $0, low $0), and average EPS is $-19.068 (high $-12.066, low $-35.278).
Did the MDGL's actual financial results beat the analysts' financial forecasts?
Based on Madrigal Pharmaceuticals's last annual report (Dec 2011), the company's revenue was $7.58M, which missed the average analysts forecast of $7.78M by -2.54%. Apple's EBITDA was $-43.968M, beating the average prediction of $-39.582M by 11.08%. The company's net income was $-47.38M, beating the average estimation of $-42.674M by 11.03%. Apple's SG&A was $11.55M, beating the average forecast of $3.3M by 250.31%. Lastly, the company's EPS was $-35.001, beating the average prediction of $-33.86 by 3.37%. In terms of the last quarterly report (Mar 2012), Madrigal Pharmaceuticals's revenue was $147K, beating the average analysts' forecast of $91.32K by 60.97%. The company's EBITDA was $-14.821M, beating the average prediction of $-13.413M by 10.50%. Madrigal Pharmaceuticals's net income was $-15.051M, beating the average estimation of $-13.621M by 10.50%. The company's SG&A was $2.65M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-9.45, beating the average prediction of $-7.81 by 21.00%